Lynn Bekris

TL;DR: Endophenotype‐based network medicine methodologies will promote AD therapeutic development that will optimize the usefulness of available data and support deep phenotyping of the patient heterogeneity for personalized medicine in AD.

TL;DR: AlzGPS as mentioned in this paper is a platform for Alzheimer's drug discovery, which integrates the genome, transcriptome, proteome, and human interactome in the drug discovery and development process to enable searching, visualizing, and analyzing multomics, various types of heterogeneous biological networks, and clinical databases for target identification and development of effective prevention and treatment for AD.

TL;DR: This work uses single-cell and single-nucleus RNA sequencing data from both AD transgenic mouse models and AD patient brains, drug-target networks, metabolite-enzyme associations, and the human protein-protein interactome to uncover conserved molecular networks between DAM and DAA, and prioritize repurposed drug candidates for potential treatment of AD.

TL;DR: Network visualization enabled by the AlzGPS offers actionable systems biology tools for accelerating therapeutic development in AD, and includes brain-specific neighborhood networks for genes-of-interest, endophenotype disease module networks for data sets- of- interest, and mechanism-Of-action networks for drugs targeting disease modules.

TL;DR: E merging blood-based biomarkers for Alzheimer disease are an exciting new development in the dementia fi eld, since they may offer a broadly accessible and relatively inexpensive screening tool.